Aster DM Healthcare was represented by Rahul Kadavakolu, Group Chief Marketing Officer, while Boehringer Ingelheim was represented by Ousama Alhaj, General Manager and Head of Human Pharma for the Near East and UAE, alongside Ghaleb Al Ahdab, Head of Public and Government Affairs for the Near East and UAE.
The partnership brings together PureHealth’s expertise in healthcare and health longevity science with Aldar’s experience in developing integrated, people-centred master-planned communities.
The approval expands the use of the therapy to delay the onset of Stage 3 Type 1 diabetes in children as young as one year old.
Khansaheb Investment LLC will transfer its 55 per cent stake, while Clemenceau Medical Company S.A.E.M.L. will sell its 25 per cent holding.
The study will use the Dexcom G7 Continuous Glucose Monitoring system, developed by a global leader in CGM technology, to assess whether continuous monitoring can improve blood sugar control when integrated into a structured, multidisciplinary care programme.
The agreements were signed during a ceremony attended by senior government officials, including Bahrain’s Minister of Education, Dr Mohammed Mubarak Juma, and Saudi Fund for Development (SFD) Chief Executive Officer Sultan Al Marshad.
The agreement was signed by Total CX Interim Chief Executive Officer Aseel Mattar and Ibn Al Nafees Hospital Chief Executive Officer Rahma Jaberi during a ceremony in Bahrain.
The partnership combines GCLS’s expertise as the world’s first higher education institution dedicated exclusively to longevity science with GMU’s academic resources and Thumbay Healthcare’s extensive clinical network across the region.
The minimally invasive procedure was carried out on a 44-year-old woman by Dr. A.B. Gopalamurugan, Structural Interventional Cardiologist at the hospital.
The initiative will support patients with the greatest medical and financial needs by improving access to advanced therapies within a framework aligned with the UAE’s national health insurance system.